Clinical Study Reports on Kerry's Sensoril Ashwagandha for Post-Menopausal Symptoms
A new randomised, double-blind, placebo-controlled clinical trial suggests Kerry's Sensoril ashwagandha may offer benefits for menopausal symptoms in post-menopausal women, potentially broadening the ingredient's application in women's health formulations.
Kerry Group has announced the publication of new clinical research investigating its Sensoril ashwagandha extract for post-menopausal women. The study, published in the *Journal of Obstetrics and Gynaecology Research*, examined the effects of Sensoril on menopausal symptoms, mood, and quality of life.
The randomised, double-blind, placebo-controlled trial involved post-menopausal women who received 125 mg of Sensoril twice daily over an eight-week period. Sensoril is a proprietary *Withania somnifera* extract standardised to 10% Withanolide glycosides.
## Reported Symptom Observations
According to the study findings, participants supplementing with Sensoril reported improvements in several menopausal symptoms compared to the placebo group. These included a reduction in the frequency and severity of hot flushes and night sweats. The research also indicated observations regarding mood disturbances, which are commonly associated with the post-menopausal transition.
Beyond specific menopausal indicators, the study reported improvements in overall quality of life scores among the Sensoril group. Additionally, participants demonstrated reductions in reported stress and anxiety levels, suggesting a potential adaptogenic effect.
## Market Implications for Women's Health
The women's health sector remains a significant growth area within the global supplement industry, with menopause support representing a key focus for product development. While ashwagandha (*Withania somnifera*) is recognised as an adaptogenic herb, specific clinical evidence for its efficacy in post-menopausal women has historically been less extensive.
This new data for a proprietary ashwagandha ingredient could inform future product development and marketing strategies within the women's health category. Manufacturers and formulators may consider such ingredients to address the multifaceted symptoms experienced by post-menopausal women.
Kerry Group funded the research, contributing to the growing body of science on botanical ingredients for targeted health concerns. The findings suggest a potential role for Sensoril in formulations aimed at supporting the well-being of post-menopausal women, aligning with consumer demand for natural health solutions in this demographic.